Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401. The main questions it aims to answer are: * Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival? * Is a single intratumoral administration of DNX-2401 safe and well tolerated? Participants will: * Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401 * Visit the clinic periodicall

Trial Details

NCT ID
NCT07424092
Phase
PHASE2
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • DNX-2401
Locations (sample)
  • Utrecht, Netherlands|52.09083,5.12222
  • Pamplona, Navarre, Spain|42.81687,-1.64323

Key Eligibility Criteria

  • The participant or participant's parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and …
  • Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors \[medulloblastomas, ATRT, EMTR, pi…
  • Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at lea…
  • Male and female participants age ≥ 1 years and ≤ 25 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →